M
Mitsufumi Nishio
Researcher at Hokkaido University
Publications - 64
Citations - 1347
Mitsufumi Nishio is an academic researcher from Hokkaido University. The author has contributed to research in topics: Transplantation & Chemotherapy. The author has an hindex of 22, co-authored 61 publications receiving 1280 citations.
Papers
More filters
Journal ArticleDOI
BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-κB pathway
Tomoyuki Endo,Mitsufumi Nishio,Thomas Enzler,Howard B. Cottam,Tetsuya Fukuda,Danelle F. James,Michael Karin,Thomas J. Kipps +7 more
TL;DR: It is found that signaling through BR3, but not BCMA or TACI, activated the alternative nuclear factor of kappa B (NF-kappaB) pathway in CLL cells, whereas signaling through BCMA/TACI induced activation of the canonical NF- kappaB pathway.
Journal ArticleDOI
Phosphatidylinositol 3-Kinase Is Involved in the Protection of Primary Cultured Human Erythroid Precursor Cells From Apoptosis
Yoshihito Haseyama,Kenichi Sawada,Atsushi Oda,Kazuki Koizumi,Hina Takano,T Tarumi,Mitsufumi Nishio,Makoto Handa,Yasuo Ikeda,Takao Koike +9 more
TL;DR: This study confirms and extends the finding that signaling in human primary cultured erythroid cells is significantly different from that in EPO-dependent cell lines and suggests that PI-3K has an antiapoptotic role in erystroid progenitor cells.
Journal ArticleDOI
Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement.
Ritsuro Suzuki,Shigeo Nakamura,Junji Suzumiya,Koichi Ichimura,Masako Ichikawa,Kiyoyuki Ogata,Yoshimasa Kura,Keiko Aikawa,Hirofumi Teshima,Masahiro Sako,Hiroshi Kojima,Mitsufumi Nishio,Tadashi Yoshino,Hiroki Sugimori,Keisei Kawa,Kazuo Oshimi +15 more
TL;DR: Blastic natural killer cell lymphoma/leukemia (BNKL) is an immature CD56‐positive neoplasm, which was recognized recently and characterized by systemic proliferation of tumor cells including skin, lymph node, and bone marrow.
Journal ArticleDOI
Excellent Outcome of Allogeneic Hematopoietic Stem Cell Transplantation Using a Conditioning Regimen with Medium-Dose VP-16, Cyclophosphamide and Total-Body Irradiation for Adult Patients with Acute Lymphoblastic Leukemia
Akio Shigematsu,Takeshi Kondo,Satoshi Yamamoto,Junichi Sugita,Masahiro Onozawa,Kaoru Kahata,Tomoyuki Endo,Soichi Shiratori,Shuichi Ota,Masato Obara,Kentaro Wakasa,Mutsumi Takahata,Yukari Takeda,Junji Tanaka,Satoshi Hashino,Mitsufumi Nishio,Takao Koike,Masahiro Asaka,Masahiro Imamura +18 more
TL;DR: Medium-dose VP/CY/TBI for adult ALL patients was associated with lower relapse rate and no increase in toxicity, resulting in better survival, and non-CR at transplantation, MRD, and no aGVHD were significant adverse prognostic factors for survival.
Journal ArticleDOI
Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group.
Masahiro Onozawa,Satoshi Hashino,Yoshifumi Haseyama,Yasuo Hirayama,Susumu Iizuka,Tadao Ishida,Makoto Kaneda,Hajime Kobayashi,Ryoji Kobayashi,Kyuhei Koda,Mitsutoshi Kurosawa,Nobuo Masauji,Takuya Matsunaga,Akio Mori,Masaya Mukai,Mitsufumi Nishio,Satoshi Noto,Shuichi Ota,Hajime Sakai,Nobuhiro Suzuki,Tohru Takahashi,Junji Tanaka,Yoshihiro Torimoto,Makoto Yoshida,Takashi Fukuhara +24 more
TL;DR: This study for the first time clarified the risk of PHN in HCT recipients and showed that advanced age is the only risk factor in autologous HCT, while graft-versus-host disease (GVHD) prophylaxis with a tacrolimus-based regimen (P = .0092; OR = 9.3) were associated with increased risk ofPHN in allogeneic HCT.